Marksans Pharma Limited (MARKSANS.BO)
- Previous Close
166.90 - Open
166.95 - Bid 171.50 x --
- Ask --
- Day's Range
166.25 - 173.85 - 52 Week Range
70.20 - 185.40 - Volume
182,447 - Avg. Volume
285,862 - Market Cap (intraday)
78.152B - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
24.39 - EPS (TTM)
7.06 - Earnings Date May 28, 2024 - Jun 1, 2024
- Forward Dividend & Yield 0.50 (0.30%)
- Ex-Dividend Date Jun 7, 2023
- 1y Target Est
31.00
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
marksanspharma.com852
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: MARKSANS.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MARKSANS.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MARKSANS.BO
Valuation Measures
Market Cap
78.01B
Enterprise Value
72.41B
Trailing P/E
23.64
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.58
Price/Book (mrq)
4.03
Enterprise Value/Revenue
3.45
Enterprise Value/EBITDA
14.48
Financial Highlights
Profitability and Income Statement
Profit Margin
15.04%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
21.03B
Net Income Avi to Common (ttm)
3.16B
Diluted EPS (ttm)
7.06
Balance Sheet and Cash Flow
Total Cash (mrq)
6.61B
Total Debt/Equity (mrq)
5.86%
Levered Free Cash Flow (ttm)
--
Research Analysis: MARKSANS.BO
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: MARKSANS.BO
MARKSANS.BO does not have Company Insights